linjc16/ctgov huggingface dataset:
The Association Between Anemia and Cardiomegaly

Study Overview
=================
Brief Summary
-----------------
Anemia is one of the major global problems that continues to this day. According to World Health Organization (WHO) data, anemia is found in 1.62 billion people or equivalent to 24.8% of the world's population while, the prevalence of anemia in children under 6 years of age in Indonesia reached 38.4%. Anemia, if undiagnosed or untreated for a long period of time can lead to multiorgan failure. The cardiovascular system is the most commonly affected system in chronic anemia. Between one-third and two-thirds of patients with severe anemia have cardiomegaly and this will return to normal within a few weeks after the anemia is well managed. This abnormality can be evaluated on chest radiograph or echocardiography.

Official Title
-----------------
The Association Between Anemia (Hemoglobin Level) and Cardiomegaly Based On Chest Radiograph and Echocardiography

Conditions
-----------------
Anemia in Children, Cardiomegaly

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anemia patients aging maximum 18 years old Anemia patients who had undergone chest radiograph and echocardiography Exclusion Criteria: Anemia patients who had undergone definitive surgery Anemia patients who had took iron supplementation in the last 3 months Anemia patients who had other anemic conditions such as chronic kidney disease or hemolytic anemia

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anemia | Diagnosis of anemia based on Hb levels according to WHO classification | April 2023 - September 2023 | 
| Cardiomegaly | Diagnosis of cardiomegaly based on chest radiograph and echocardiography | April 2023 - September 2023 |
An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.

Detailed Description
-----------------
ESCC patients with II-IVA resection will undergo MRD examination at the following time: the first examination is before the operation, the second examination is 7-10 days after the operation, and then 1 month after the operation, 2 weeks after the end of adjuvant treatment (if available), the follow-up period (every 3 months if there is no postoperative treatment) and the progress (the progress of the disease confirmed by the researcher), the patients will receive close MRD monitoring to evaluate the correlation between ctDNA-MRD and therapeutic efficacy and prognosis.

Official Title
-----------------
Application of ctDNA-MRD in the Prediction of Curative Effect, Recurrence Monitoring and Prognosis Evaluation of Esophageal Squamous Cell Carcinoma (ESCC) During Perioperative Treatment

Conditions
-----------------
Squamous Cell Carcinoma of Esophagus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with stage II-IVA Esophageal squamous cell carcinoma confirmed by clinical pathological staging; ≥18 years; Eastern Cooperative Oncology Group performance status score (ECOG PS) is 0   1 points; Expected survival time ≥ 6 months; Patients agree and have the ability to follow the planned study visits, laboratory tests and other research steps. Exclusion Criteria: Patients with other malignant tumors; Patient had undergone surgery before admission; Pregnant or lactating women; Patients with other serious diseases; Patients who could not understand the experiment content and could not cooperate with them and refused to sign the informed consent form; Patients with contraindications to radiotherapy and chemotherapy; Other researchers think it is not suitable.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Evaluation of progression-free survival rate of esophageal squamous cell carcinoma patients with different MRD status during perioperative period | up to 2 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ESCC, ctDNA
Study of Visceral Fat in type2diabetic Patients and Its Relation to Microvascular Complications

Study Overview
=================
Brief Summary
-----------------
Study the correlation between METS IR and visceral fat in type 2 diabetes and its relation to microvascular complication

Detailed Description
-----------------
The Metabolic Score for Insulin Resistance (METS-IR) is a metabolic index developed with the aim to quantify peripheral insulin sensitivity in humans; it was first described under the name METS-IR by Bello-Chavolla et al in 2018. It was developed by the Metabolic Research Disease Unit at the Institute National de Ciencias Médicas Salvador Zubirán and validated against the euglycemic hyperinsulinemic clamp and the frequently-sampled intravenous glucose tolerance test in Mexican population.It is a non-insulin-based alternative to insulin-based methods to quantify peripheral insulin sensitivity and an alternative to the Homeostatic Model Assessment (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI). Very limited research correlate between visceral obesity and microvascular complications in type 2 diabetic patients and how can the metabolic score for insulin resistance predict visceral obesity and microvascular complications in type2 diabetic patients. In this study the investigators will search for these correlations.

Official Title
-----------------
Study of Visceral Fat in Type 2diabetic Patients and Its Relation to Microvascular Complications

Conditions
-----------------
Visceral Fat, Insulin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Both male and female subjects Subjects capable of giving consent and voluntarily willing to participate in the study Exclusion Criteria: Chronic kidney disease patients Any nondiabetic nephropathy patients Patients affected by hypertension Patients affected by ocular disorders Neuropathies of other etiologies like chronic liver disease patients, alcoholics, or drug addicts Critically ill patients of type 2 diabetes mellitus Patients who have not given consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between METS IR and visceral fat in type 2 diabetes | Study the cor relation between METS IR and visceral fat in type 2 diabetes and its relation to microvascular complication | one year |
Effects of Different Anesthetic Gases on Hemodynamics, Arterial Oxygenation and Lung Mechanics

Study Overview
=================
Brief Summary
-----------------
The bronchodilator effects of volatile anesthetics have been the subject of many clinical studies. It is known that all volatile anesthetics, especially halothane, have similar effects. Sevoflurane has been shown to reduce airway resistance more than halothane and isoflurane. Desflurane is difficult to use as an induction agent due to its harsh and extremely pungent odor and airway irritating effect. However, it has been shown that the risk of cough, respiratory arrest and laryngospasm is no different from sevoflurane when administered after intravenous induction. Although it irritates the airway, it is thought to have a bronchodilation effect as it stimulates the sympathetic system. In spinal surgeries, prone position is required to access the operating field. When the patient is placed in the prone position, pulmonary physiology are affected. In the prone position, V/Q mismatch decreases and arterial oxygenation increases. However, lung compliance decreases and the peak inspiratory pressure required to reach the required tidal volume increases. The main purpose of this study is the effect of volatile agents on lung mechanics and oxygenisation in the prone position.

Official Title
-----------------
Evaluation of the Effects of Different Anesthetic Gases on Hemodynamics, Arterial Oxygenation and Lung Mechanics in Spinal Surgery.

Conditions
-----------------
Oxygenation, Spinal Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years old ASA1-2 Patients planned to undergo spinal surgery Exclusion Criteria: 1 - Lung disease BMI 35 and above Smokers Those under the age of 18 and over the age of 65 Hepatorenal disease Reynaud's disease Burger disease Hypotensive patient Neuromuscular disease Those who have had thoracic surgery before Those with bad Allen test results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| sevoflurane<br> | |
| desflurane<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compliance | pulmonary compliance before, during and after prone position | 2 hour |
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1567 in Healthy Adult Volunteers

Study Overview
=================
Brief Summary
-----------------
This study aims to compare the pharmacokinetics and safety following administration of DWJ1567 and DWC202312 in healthy volunteers

Detailed Description
-----------------
The study design is a Randomized, Open-label, Oral, Single-dose, Four-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUCt of DWJ1567 and DWC202312. Secondary endpoints were AUCinf, Tmax, t1/2 of DWJ1567 and DWC202312.

Official Title
-----------------
An Open-label, Randomized, 2x4 Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of DWJ1567 and DWC202312 in Healthy Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: DWJ1567
* Drug: DWC202312


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 19 year old Exclusion Criteria: Galactose intolerance Lapp lactase deficiency

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DWJ1567<br>DWJ1567 | Drug: DWJ1567<br>* One tablet of DWJ1567<br>|
| Active Comparator: DWC202312<br>DWC202312 | Drug: DWC202312<br>* One tablet of DWC202312<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax,ss of DWJ1567 and DWC202312 |  | At pre-dose (0 hour), and post-dose 0 to 72 hour. | 
| AUCt of DWJ1567 and DWC202312 |  | At pre-dose (0 hour), and post-dose 0 to 72 hour. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf of DWJ1567 and DWC202312 |  | At pre-dose (0 hour), and post-dose 0 to 72 hour | 
| Tmax of DWJ1567 and DWC202312 |  | At pre-dose (0 hour), and post-dose 0 to 72 hour | 
| AUCt/AUCinf of DWJ1567 and DWC202312 |  | At pre-dose (0 hour), and post-dose 0 to 72 hour | 
| t1/2 of DWJ1567 and DWC202312 |  | At pre-dose (0 hour), and post-dose 0 to 72 hour |
Diastolic Deceleration Area in Late-onset FGR

Study Overview
=================
Brief Summary
-----------------
DDA is a new Doppler parameter aiming to assess fetal well-being in-utero. Late-onset FGR is a specific subgroup of fetuses where the clinical application of this Doppler modality could play an essential role in detecting hypoxia, anemia, and other adverse neonatal outcomes.

Official Title
-----------------
Diastolic Deceleration Area (DDA) in Late-onset Fetal Growth Restriction (FGR)

Conditions
-----------------
Hypoxia, Anemia

Intervention / Treatment
-----------------
* Device: DDA Doppler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: absence of fetal abnormalities and/or genetic conditions; single pregnancy; fetal growth restriction (FGR) < 10%, according to the INTERGROWTH 21st nomograms, appearing after 32nd week of gestation Exclusion Criteria: documented fetal abnormalities and/or genetic conditions in the course of the pregnancy; multiple pregnancy; absence of fetal growth restriction (FGR) < 10%, according to the INTERGROWTH 21st nomograms after 32nd week of gestation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 48 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Standard care: Doppler velocimetry: UA & MCA PI, DV PIV, CPR; Indirect cardiotocography (CTG) Biophysical profile (BPP) | |
| DDA Doppler group<br>Standard care plus DDA Doppler monitoring | Device: DDA Doppler<br>* A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoxia in the newborn | Defined by pH values < 7.20 | immediately after delivery | 
| Anemia in the newborn | Hemoglobin deviation from GA mean - mild < 20 g/L, moderate - 20-70 g/L, severe > 70 g/L | immediately after delivery | 
| Occurence of hypoxic-ischemic encephalopathy | Occurence of hypoxic-ischemic encephalopathy in relation to some of the outcome measures | first 72 hours after delivery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apgar score at 1st minute | Apgar score measured at 1st minute after delivery | 1 minute after delivery | 
| Apgar score at 5th minute | Apgar score measured at 5th minute after delivery | 5 minutes after delivery | 
| Apgar score at 10th minute | Apgar score measured at 10th minute after delivery | 10 minutes after delivery | 
| Admissions to a NICU | Admissions to a NICU indicated by or related to some of the outcome measures | first 72 hours after delivery |
Longitudinal HPV Pap in CIN and VAIN

Study Overview
=================
Brief Summary
-----------------
This study will construct a longitudinal risk model of VaIN according to the HPVs distribution of cervix and vaginal for those had CIN2+. The study will include three arms to complete the follow-up data for the previous cohort constructed, and prospectively recruit new subjects with the appropriate inclusion/excluding criteria in order to increase sample size of this study.

Detailed Description
-----------------
The long-term outcomes of patients with antecedent cervical intraepithelial neoplasia (CIN) were lacking. A systematic review published in 2008 identified no studies that met the review eligibility criteria for the prevalence of HPV types among vaginal precursors and cancers. Two sporadic studies containing 16 and 81 cases were reported in that review. Given that vaginal intraepithelial neoplasia (VAIN) post-hysterectomy for CIN is an uncommon disease which has a prevalence of being 1 to 6 %; it has the potential to progress to malignancy. Although the etiology of VAIN has not been as thoroughly investigated as that of CIN, evidence implicates that the human papillomavirus (HPV) as the probable carcinogenic agent for the onset and evolution of some VAIN and vaginal cancers. This study will construct a longitudinal risk model of VaIN according to the HPVs distribution of cervix and vaginal for those had CIN2+.

Official Title
-----------------
Longitudinal Study of Human Papillomavirus (HPV) Genotyping and Pap Smear in Patients With Antecedent Cervical Intraepithelial Neoplasia (CIN) and Association With Vaginal Intraepithelial Neoplasia (VAIN)

Conditions
-----------------
Cervical Intraepithelial Neoplasia, Hysterectomy, Human Papillomavirus, Vaginal Intraepithelial Neoplasia

Intervention / Treatment
-----------------
* Other: HPV test and Pap Smear


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >= 20 years Those with a previous history of CIN+

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CIN_Group<br>Those with a previous history of cervical cancer or CIN before incident VaIN and those with VaIN detected concomitantly with cervical cancer or CIN for whom both vaginal biopsy and cervical specimens were available in our hospital were eligible. | Other: HPV test and Pap Smear<br>* HPV test and Pap Smear<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression rate of CIN+ or VaIN+ | time to developing CIN+ or VaIN+ from first CIN+ diagnosis | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical Intraepithelial Neoplasia, hysterectomy, human papillomavirus, vaginal intraepithelial neoplasia
Perceptions and Prevalence of Workplace Violence in Healthcare

Study Overview
=================
Brief Summary
-----------------
Workplace violence includes physical and verbal aggression as well as threatening behavior. All types of workplace violence incidents in health care are often under-reported, especially if there is no lasting physical injury.

Detailed Description
-----------------
Research reveals that healthcare workers are three times more likely to experience workplace violence than any other occupation. The first step toward reducing the occurrence of violence is to understand the perceptions and prevalence of workplace violence.

Official Title
-----------------
Perceptions and Prevalence of Workplace Violence in Healthcare

Conditions
-----------------
Violence

Intervention / Treatment
-----------------
* Other: No intervention.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must be employed full-time, part-time, or per diem Exclusion Criteria: Inability to read English will cause a staff member to be excluded from the study, as the survey is written in English.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Methodist Health System Employees<br>All MHS employees, clinical and non-clinical. | Other: No intervention.<br>* The subjects will complete a survey related to workplace violance.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level and type of workplace violence | Research Instruments Survey Questionnaire used to measure physical and psychological characteristics of violence at work | Period of 6 months | 
| Impact on the individual employee/worker | Self-reported consequences in relation to work (e.g., distress/burnout, transfer/quits, absenteeism, financial situation, career path) | Period of 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Research Instruments Survey Questionnaire | Survey Monkey will be used to measured Frequency of reported incidents concerning the different forms of violence at work | Period of 6 months | 
| Self-reported impact of violence on quality of care for patients | Impact on the organization (e.g., cost data, lost work days, staff fluctuation, staff shortage) | Period of 6 months |
Effectiveness of the Dry Needling Approach in Patients With Tension-Type Headache

Study Overview
=================
Brief Summary
-----------------
Randomized Single-Blind Clinical Trial in which the treatment will be administered through 3 sessions of dry needling in the cervical, cranial, and facial musculature in patients with frequent and chronic tension-type headache.

Official Title
-----------------
Effectiveness of the Dry Needling Approach in Patients With Tension-Type Headache

Conditions
-----------------
Tension-Type Headache, Dry Needling

Intervention / Treatment
-----------------
* Other: Dry Needling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of tension headache according to IHS Exclusion Criteria: Documented major trauma through medical history in the cervical area and/or recent surgery. Pregnancy. Generalized pain. Inflammatory, hormonal, or neurological disorders. Tendon disorders in the upper extremities. Severe psychiatric illnesses. Inability to complete the form in Spanish. Having a pacemaker (due to the use of equipment with magnetic sensors). Specific contraindications to invasive or conservative physiotherapy (infection, fever, hypothyroidism, wounds in the puncture area, metal allergies, cancer, systemic diseases, or belonephobia). Having received physiotherapy treatment for the condition in the past month.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dry Needling group<br> | Other: Dry Needling<br>* 3 treatment to eliminate active trigger points that patients have<br>|
| No Intervention: Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Active trigger points | The investigators assess the sensitivity of trigger points using algometry to determine which points reproduce the participants tensional-type headache. | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cervical ROM | general cervical range of movement, upper and lower cervical | 1 month |